Xanthine oxidoreductase in respiratory and cardiovascular disorders.
about
Xanthine Oxidoreductase-Derived Reactive Species: Physiological and Pathological EffectsThe heart is an early target of anthrax lethal toxin in mice: a protective role for neuronal nitric oxide synthase (nNOS).Xanthine oxidase inhibition by febuxostat attenuates stress-induced hyperuricemia, glucose dysmetabolism, and prothrombotic state in miceXanthine oxidoreductase promotes the inflammatory state of mononuclear phagocytes through effects on chemokine expression, peroxisome proliferator-activated receptor-{gamma} sumoylation, and HIF-1{alpha}N-acetylcysteine and allopurinol confer synergy in attenuating myocardial ischemia injury via restoring HIF-1α/HO-1 signaling in diabetic rats.The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes.The anti-oxidative role of micro-vesicles derived from human Wharton-Jelly mesenchymal stromal cells through NOX2/gp91(phox) suppression in alleviating renal ischemia-reperfusion injury in ratsCyclin-dependent kinase five mediates activation of lung xanthine oxidoreductase in response to hypoxia.Vascular endothelial function is not related to serum uric acid in healthy adults.Metabolomic markers of altered nucleotide metabolism in early stage adenocarcinomaThe tyrosine kinase inhibitor imatinib prevents lung injury and death after intravenous LPS in mice.Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease.Structural and functional insights into the catalytic inactivity of the major fraction of buffalo milk xanthine oxidoreductase.Nitrate decreases xanthine oxidoreductase-mediated nitrite reductase activity and attenuates vascular and blood pressure responses to nitrite.Innate immune recognition in infectious and noninfectious diseases of the lung.Xanthine oxidoreductase: a journey from purine metabolism to cardiovascular excitation-contraction coupling.Lung oxidative damage by hypoxiaNADPH oxidases as a source of oxidative stress and molecular target in ischemia/reperfusion injury.The role of uric acid in the pathogenesis of human cardiovascular disease.The high-risk patient with heart failure with reduced ejection fraction: treatment options and challenges.Novel insights into redox system and the mechanism of redox regulation.XOR inhibition with febuxostat accelerates pulmonary endothelial barrier recovery and improves survival in lipopolysaccharide-induced murine sepsis.Febuxostat, a novel xanthine oxidoreductase inhibitor, improves hypertension and endothelial dysfunction in spontaneously hypertensive rats.Reactive oxygen species and the control of vascular function.Redox-Dependent Calpain Signaling in Airway and Pulmonary Vascular Remodeling in COPD.2-Benzamido-4-methylthiazole-5-carboxylic Acid Derivatives as Potential Xanthine Oxidase Inhibitors and Free Radical Scavengers.Combined effects of sivelestat and resveratrol on severe acute pancreatitis-associated lung injury in rats.Comprehensive metabonomic analysis of heart tissue from isoproterenol-induced myocardial infarction rat based on reversed-phase and hydrophilic interaction chromatography coupled to mass spectrometry.Age-related changes in xanthine oxidase activity and lipid peroxidation, as well as in the correlation between both parameters, in plasma and several organs from female mice.Acquired xanthine dehydrogenase expression shortens survival in patients with resected adenocarcinoma of lung.Potential xanthine oxidase inhibitory activity of endophytic Lasiodiplodia pseudotheobromae.Vascular Function and Uric Acid-Lowering in Stage 3 CKD.
P2860
Q26773007-894D5ED1-74F7-4499-B483-5E473ABAEB3FQ33455537-8C6FDB04-7600-4EB5-BA1E-73EB25BDA70CQ33683082-599467ED-3B76-4132-801E-9B386D7B4EE4Q34489192-91A7E9E6-536B-4D49-8FF9-9C9C968E5EC6Q34852014-CB417BA3-8DAF-4458-B216-3DBC78707798Q35115789-B886A7D0-B363-4EE2-816C-52E06D7949CDQ35122712-833A664E-60F5-4C70-BBD9-27039DDA8B4BQ35592092-0CC9ADB0-0B84-4827-8E6F-574D4E3992E9Q35843077-A8A552D5-3A47-4F68-8A1A-3EE7B925DACEQ36201742-0D00D725-C05D-4915-B99F-4EA9CDB7F035Q36357495-1F34374B-7428-43C4-8426-C7E0C8584501Q37175244-A2366658-8512-4659-ABDC-8A3AD8E4C49AQ37539045-265A97A9-818E-4D57-B446-5E9F574A7404Q37693731-9EB21ACF-F42C-423C-B7D0-CF289172FF07Q37694915-BF1921FB-5955-4D4C-BC20-24B9F79DA5BDQ37903030-A1BCFB2E-B7F5-4F05-B0A7-835703B3B6E9Q38042426-2219A0DB-EFD3-4CE0-8867-7BBD69574F63Q38054458-DF3C0AA0-1A6C-4BE8-9D07-F70D2924131DQ38076242-FE7FFBC5-FA90-4735-9DBC-6A31773C3709Q38121483-F05C4C69-D005-4109-A1BC-07DE03A4A12BQ38851856-EF83920B-49CE-489F-9B7D-938BA90DAA19Q41386068-7303EFA1-0BD5-4FA1-8D12-E609B5591AC4Q42152252-E674049D-1A0C-46FE-819F-191B516B2A36Q43157291-4BBABE9E-3395-441D-87F4-E84F2D658E0AQ46280869-5C66C7D9-3AD7-4E9F-A9D1-0E56A331BCECQ46426129-258A26AC-06D5-4768-A694-4D755AA4FC54Q46899476-454657D3-21B9-4F2C-BEDA-063DDE8CC486Q48329169-B28F827D-19AD-4C8A-8298-2A2B262F5339Q51456636-7C7C30C7-D8EE-48BB-8E25-E39BFD639715Q54306088-E4EE960F-817B-47B8-A9C4-27A677B7D90DQ54458504-830DEEDC-6797-47D3-AFB1-DBA74346FCF2Q55077663-18BD7CD4-ADD3-4466-BB02-EF36B7539E0C
P2860
Xanthine oxidoreductase in respiratory and cardiovascular disorders.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Xanthine oxidoreductase in respiratory and cardiovascular disorders.
@en
Xanthine oxidoreductase in respiratory and cardiovascular disorders.
@nl
type
label
Xanthine oxidoreductase in respiratory and cardiovascular disorders.
@en
Xanthine oxidoreductase in respiratory and cardiovascular disorders.
@nl
prefLabel
Xanthine oxidoreductase in respiratory and cardiovascular disorders.
@en
Xanthine oxidoreductase in respiratory and cardiovascular disorders.
@nl
P2093
P2860
P1476
Xanthine oxidoreductase in respiratory and cardiovascular disorders.
@en
P2093
Adel Boueiz
Mahendra Damarla
Paul M Hassoun
P2860
P304
P356
10.1152/AJPLUNG.00007.2008
P577
2008-03-14T00:00:00Z